Mustang Bio stock gets April 2027 Nasdaq deadline
Published on 11/05/2026 at 04:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSNasdaq Relief Extends Mustang's Runway
- Nasdaq granted Mustang Bio an additional cure period after the company failed to regain compliance with the minimum bid-price rule.
- Compliance requires a closing bid of at least 1.00 dollar for 10 consecutive business days.
- Mustang Bio may consider a reverse split, but the company offered no assurance that it will retain its listing.
Mustang Bio faces a longer timetable to restore compliance with Nasdaq's minimum bid-price rule after the exchange granted a second cure period. The Globe and Mail reported on Friday, October 16, that Nasdaq gave the company until April 12, 2027, after it failed to meet the first deadline.
Nasdaq Extends Compliance Window
The company had received an initial notice after its common stock closed below 1.00 dollar for 30 consecutive business days. That first cure period ended on October 12, 2026, without Mustang Bio regaining compliance.
The additional period requires a closing bid of at least 1.00 dollar for at least 10 consecutive business days, generally no more than 20. If Mustang Bio does not meet the requirement by the new deadline, Nasdaq staff can notify the company that its shares will be delisted.
Mustang Bio said it intends to monitor the closing bid and consider available measures, including a reverse stock split if necessary. The company also said there is no assurance that it will regain compliance or remain listed.
Clinical Pipeline Drives Strategy
Mustang Bio is a U.S. clinical-stage biopharmaceutical company focused on cell therapies for difficult-to-treat cancers and autoimmune diseases. Its programs include MB-106, a CD20-targeted CAR T-cell therapy, and programs aimed at glioblastoma and other serious diseases.
Company Focus And Position
Mustang Bio develops and licenses cell- and gene-therapy programs and seeks to advance them through research, partnerships and potential commercialization. Its main focus is the U.S. market, with programs targeting cancer and autoimmune diseases. As a small clinical-stage specialist, Mustang occupies a narrower development position than diversified pharmaceutical companies, with its prospects tied closely to the progress of its therapy pipeline.
Mustang Bio at a Glance
- Company: Mustang Bio, Inc.
- ISIN: US62818Q3020
- Ticker: MBIO
- Home exchange: Nasdaq Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters: Waltham, Massachusetts, United States
Broader U.S. market conditions remain relevant for investors following biotechnology stocks; see the S&P 500 market theme.
More news and analyses on Mustang Bio stock.
